Atypical fractures of the femur below the lesser trochanter have been reported in patients
treated with bisphosphonates. We performed a systematic literature search of case/case …

This paper reviews the evidence for an association between atypical subtrochanteric
fractures and long-term bisphosphonate use. Clinical case reports/reviews and case–control …

Reports linking long‐term use of bisphosphonates (BPs) with atypical fractures of the femur
led the leadership of the American Society for Bone and Mineral Research (ASBMR) to …

Bone health and maintenance of bone integrity are important components of comprehensive
cancer care. Many patients with cancer are at risk for therapy-induced bone loss, with …

Aims Treatment guidelines for atypical femoral fractures associated with bisphosphonates
have not been established. We conducted a systematic review of the treatment of atypical …

Use of bisphosphonates has been growing steadily in the last decade. This follows the
introduction of simpler dosing regimes, the availability of lower-priced generics, and …

Atypical femoral fractures (AFF) associated with long‐term bisphosphonates (LTB) are a
growing concern. Their etiology is unknown, but bone material properties might be …

We performed a retrospective review of all patients admitted to two large University
Hospitals in the United Kingdom over a 24-month period from January 2008 to January …

There have been recent concerns about the safety of proton pump inhibitors (PPIs). We
focus here on 3 specific concerns—the possible interaction between PPIs and clopidogrel …

Background: Atypical subtrochanteric femoral fractures have been identified as a potential
complication of long-term bisphosphonate therapy for the treatment of osteoporosis. Patients …